
RealRate

PHARMACEUTICAL 2022

ARROWHEAD PHARMACEUTICALS of arrowhead pharmaceuticals INC.



Rank 247 of 466





RealRate

PHARMACEUTICAL 2022

ARROWHEAD PHARMACEUTICALS of arrowhead sharmaceuticals INC.



Rank 247 of 466

The relative strengths and weaknesses of ARROWHEAD PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARROWHEAD PHARMACEUTICALS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 54% points. The greatest weakness of ARROWHEAD PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 111%, being 33% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	384,597
Cost of Goods Sold	0
Intangible Assets	13,663
Liabilities, Current	146,536
Liabilities, Non-Current	154,790
Other Assets	263,213
Other Compr. Net Income	-87
Other Expenses	2.0
Other Liabilities	0
Other Net Income	8,190
Other Revenues	138,287
Property and Equipment	48,675
Research and Development	206,342
Selling, General and Administrative Expense	80,981

Output Variable	Value in 1000 USD
Assets	710,148
Liabilities	301,326
Expenses	287,325
Revenues	138,287
Stockholders Equity	408,822
Net Income	-140,848
Comprehensive Net Income	-140,892
Economic Capital Ratio	111%

